 |
|
|
|
|
|
|
|
|
|
|
 |
|
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
|
||
 |
 |
 |
|
|||||||
 |
|
|||||||||
 |
|
|||||||||
Alert Number 233
Date: May 16, 2024
Bexxar and Zevalin are two radio-immunotherapy drugs that have generated a great deal of excitement in follicular lymphoma.
An innovative clinical trial at the Fred Hutchinson Cancer Research Center (the “Hutch”, Seattle) has finally put Bexxar within reach of previously untreated CLL patients. This is an important clinical trial and I would like to encourage all of you to familiarize yourselves with the concepts involved. Bexxar is a commercially available drug, within the reach of practicing oncologists and patients today. This is no pie-in-the-sky experimental drug that may take many years before it can be formally prescribed by oncologists.
Track record of Bexxar in NHL is pretty impressive. How many of us would like to go for a therapy that gives a high probability of response, reasonably low toxicity, definitely low hassle and a pretty good shot at a 6-year remission? If you are the type that likes to try for a robust and potentially long-lasting remission upfront from your frontline therapy, this clinical trial may be just right for you. You can read all about it in our review of the RF + Bexxar clinical trial.
Be well,
Chaya
______
NOTICE: This page from the Topics Alert archive was originally emailed to subscribers of Topics Alert, a free service of CLL Topics Inc. If you are not a subscriber and you wish to receive email Alerts, please register at the Topics Alert subscription page. The content of this page is intended for information only and it is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
———
Disclaimer: The content of this website is intended for information only and is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
Copyright Notice:
Copyright © 2024-2007 CLL Topics, Inc. All Rights Reserved.
All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of CLL Topics, Inc. You may not alter or remove any trademark, copyright or other notice from copies of the content.
However, you may download and print material from CLLTopics.org exclusively for your personal, noncommercial use.
———
